Amlodipine (Besylate) - Indications, dose, side effects ...

Strong calcium channel blocker amlodipine is used to treat the following conditions:

  • Symptomatic chronic stable angina
  • Treatment of confirmed or suspected vasospastic angina
  • Treatment of hypertension.
  • Raynaud's phenomenon

Amlodipine Dose in Adults 

  • Amlodipine dose in chronic stable angina:
    • 5 to 10 mg orally once daily. Beta-blocker should be used as the first line anti-anginal agent. Amlodipine may be added to beta-blocker if symptoms of angina persist or the patient remains symptomatic despite using a beta-blocker.
  • Vasospastic angina:
    • 5 to 10 mg orally once daily in combination with a nitrate.
  • Hypertension:
    • Start your treatment with a dose of 2.5 to 5 mg once daily, up to a maximum of 10 mg once daily. Amlodipine can be used alone or in combination with different medicines, such as thiazide diuretics, ACE inhibitors, or ARBs.
  • Amlodipine dose in Raynaud phenomenon:
    • 5 mg once daily up to 20 mg once daily is the maximum dosage.

Amlodipine Dose in Children

Amlodipine dose in children with Hypertension:

  • Children 1 - 5 years of age:
    • Initial doses of 0.05-0.1 mg/kg/day.
  • Children and Adolescents 6 to 17 years of age:
    • 2.5 to 5 mg once daily.
    • Weight-based dosing can be as low as 0.06 mg/kg/day and as high as 0.34 mg/kg/day (but not more than 10 mg/day).

Pregnancy Risk factor C

  • Amlodipine is not recommended for pregnant women. It crosses the placenta. 
  • Since maternal hypertension may be related to serious adverse outcomes, amlodipine may be used, especially if other agents cannot be used.

Amlodipine use during breastfeeding

  • Breast milk contains very little amlodipine. 
  • Negative neonatal outcomes have never been reported. Amlodipine can be used in conjunction with breastfeeding.

Amlodipine Dose in Renal Disease:

  • Dosage adjustment in kidney disease and patients on hemodialysis is not required.

Amlodipine Dose in Liver Disease:

  • Patients with severe liver disease may require a lower initial dose i.e. 2.5 mg. The dose should be titrated very slowly. 

Common side effects of amlodipine:

  • Cardiovascular:
    • Peripheral edema
  • Respiratory:
    • Pulmonary edema
  • Cardiovascular:
    • Palpitations and flushing
  • Central nervous system:
  • Dermatologic:
    • Pruritus and skin rash
  • Gastrointestinal:
    • Nausea, constipation and abdominal pain
  • Neuromuscular & skeletal:
    • Muscle cramps and weakness.
  • Respiratory:
    • Dyspnea

Contraindications to Amlodipine include:

  • Allergy reactions to amlodipine and any component of the formulation
  • Allergies to medicines from the same group.
  • Severe hypotension (SBP less than 90mm Hg).

Warnings and Precautions

  • Angina and Myocardial infarction:
    • In the absence of a beta-blocker, reflex tachycardia can occur. This may lead to angina or myocardial infarction.
  • Peripheral edema
    • After 2 to 3 weeks, edema can be seen as the most common side effect.
  • Aortic stenosis and hypertrophic cardiomyopathy:
    • Ischemia may occur in patients suffering from severe aortic narrowing. It may cause an increase in the afterload for patients with HCM. These patients should be cautious when using it.
  • Heart failure:
    • Patients with heart disease and reduced ejection fraction should avoid calcium channel blockers other that amlodipine.

Amlodipine: Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy).

Alfuzosin May intensify blood pressure lowering medications' hypotensive effects.
Alpha1-Blockers May intensify calcium channel blockers' hypotensive effects.
Amphetamines May lessen the effects of antihypertensive medications in treating hypertension.
Antipsychotic Agents, Second Generation (Atypical) Antipsychotic drugs can have a greater hypotensive effect when blood pressure-lowering medications are used (Second Gen [Atypical]).
Aprepitant High risk of inhibitors increasing serum CYP3A4 substrate concentrations. It's crucial to keep an eye out for any heightened pharmacologic effects of aripiprazole. Depending on the indication and/or concurrent medication, aripiprazole dosage modifications may be required. Consult the interaction monograph in its entirety for more details.
ARIPiprazole Weak CYP3A4 Inhibitors may raise serum levels of ARIPiprazole.
Atosiban Calcium channel blockers may make atosiban's toxic/unwanted effects worse. The likelihood of developing pulmonary edoema or dyspnea may rise.
Barbiturates Metabolism may be boosted by calcium channel blockers. Monitoring: When calcium channel blockers are administered in conjunction with barbiturate medication, look for any diminished therapeutic effects. It could be necessary to change the dosage of calcium channel blockers. The concurrent use of phenobarbital and nimodipine is not recommended.
Barbiturates May intensify blood pressure lowering medications' hypotensive effects.
Benperidol May intensify blood pressure lowering medications' hypotensive effects.
Bosentan Could decrease serum levels of CYP3A4 substrates (High Risk with Inducers).
Brigatinib May lessen the effects of antihypertensive medications in treating hypertension. The bradycardic effects of antihypertensive medications may be exacerbated by brutinib.
Brimonidine (Topical) Might increase the hypotensive effects of Blood Pressure Lowering Agents.
Calcium Channel Blockers (Nondihydropyridine) Dihydropyridine, a calcium channel blocker, may increase the hypotensive effects of calcium channel blockers (Nondihydropyridine). Nondihydropyridine may raise the serum level of calcium channel blockers (Dihydropyridine).
Calcium Salts The therapeutic benefits of calcium channel blockers can be lessened as a result.
Clofazimine High likelihood that inhibitors will raise serum concentrations of CYP3A4 substrates
Clopidogrel Calcium channel blockers may reduce the therapeutic effects of clopidogrel.
CycloSPORINE Systemic Dihydropyridine, a calcium channel blocker, may raise the serum level of CycloSPORINE Systemic. The serum levels of calcium channel blockers (Dihydropyridine) may increase after using CycloSPORINE Systemic.
Moderate CYP3A4 Inducers Could decrease serum levels of CYP3A4 substrates (High Risk with Inducers).
Moderate CYP3A4 inhibitors May raise serum levels of amelodipine
Strong CYP3A4 inhibitors May increase serum AmLODIPine concentrations
Dapoxetine May intensify calcium channel blockers' orthostatic hypotensive effects.
Deferasirox Could decrease serum levels of CYP3A4 substrates (High Risk with Inducers).
Dexmethylphenidate Antihypertensive agents may have a less therapeutic effect.
Diazoxide May intensify blood pressure lowering medications' hypotensive effects.
Dofetilide CYP3A4 inhibitors could increase the amount of dofetilide (Weak).
DULoxetine By reducing blood pressure, DULoxetine may exacerbate hypotension.
Duvelisib High likelihood that inhibitors will raise serum concentrations of CYP3A4 substrates
Efavirenz Decrease serum calcium channel blockers
Flibanserin CYP3A4 inhibitors may result in an increase in flibanserin (Weak).
Fluconazole Serum calcium channel blockers may rise.
Fosaprepitant High likelihood that inhibitors will raise serum concentrations of CYP3A4 substrates
Fosnetupitant High risk of Inhibitors causing an increase in serum CYP3A4 Substrates concentrations
Herbs (Hypertensive Properties) May lessen the effects of antihypertensive medications in treating hypertension.
Herbs (Hypotensive properties) May intensify blood pressure lowering medications' hypotensive effects.
Hypotension-Associated Agents The hypotensive action of hypotension-associated agents may be strengthened by blood pressure lowering medications.
Ivosidenib Could lower serum concentrations of CYP3A4 substrates (High Risk with Inducers).
Larotrectinib High likelihood that inhibitors will raise serum concentrations of CYP3A4 substrates
Levodopa-Containing Products Levodopa-Containing Products' hypotensive effects may be amplified by blood pressure-lowering medications.
Lormetazepam May intensify blood pressure lowering medications' hypotensive effects.
Lovastatin AmLODIPine may raise the serum levels of lovastatin.
Magnesium Salts Magnesium salts can have more hazardous or harmful effects when taken with calcium channel blockers. The hypotensive effects of calcium channel blockers can be enhanced by magnesium salts.
Melatonin Dihydropyridine, a calcium channel blocker, may have less antihypertensive effects.
Methylphenidate May lessen the effects of antihypertensive medications in treating hypertension.
Molsidomine May intensify blood pressure lowering medications' hypotensive effects.
Naftopidil May intensify blood pressure lowering medications' hypotensive effects.
Netupitant High likelihood that inhibitors will raise serum concentrations of CYP3A4 substrates
Neuromuscular-Blocking Agents (Nondepolarizing) The neuromuscular-blocking impact of neuromuscular-blocking agents may be enhanced by calcium channel blockers (Nondepolarizing).
Nicergoline May intensify blood pressure lowering medications' hypotensive effects.
Nicorandil May intensify blood pressure lowering medications' hypotensive effects.
NiMODipine NiMODipine serum levels may rise in response to weak CYP3A4 inhibitors.
Nitrogen Blood pressure lowering medications may intensify Nitroprusside's hypotensive effects.
Palbociclib High likelihood that inhibitors will raise serum concentrations of CYP3A4 substrates
Pentoxifylline May intensify blood pressure lowering medications' hypotensive effects.
Pholcodine Pholcodine's ability to reduce blood pressure may help to increase hypotensive effects.
Phosphodiesterase 5 Inhibitors May intensify blood pressure lowering medications' hypotensive effects.
Prostacyclin Analogues May intensify blood pressure lowering medications' hypotensive effects.
Quinagolide May intensify blood pressure lowering medications' hypotensive effects.
QuiNIDine Dihydropyridine, a calcium channel blocker, may raise the serum levels of quinine. The serum concentration of calcium channel blockers (Dihydropyridine) may rise in response to quinine. Dihydropyridine, a calcium channel blocker, may reduce the serum levels of quinine.
Sarilumab Could decrease serum levels of CYP3A4 substrates (High Risk with Inducers).
Siltuximab Could decrease serum levels of CYP3A4 substrates (High Risk with Inducers).
Simeprevir High likelihood that inhibitors will raise serum concentrations of CYP3A4 substrates
Tacrolimus (Systemic) Dihydropyridine, a calcium channel blocker, may raise the serum concentrations of tacrolimus.
Tocilizumab Could decrease serum levels of CYP3A4 substrates (High Risk with Inducers).
Yohimbine Antihypertensive medications may not have as much of an effect.

Risk Factor D (Regard therapy modification)

 
Amifostine The hypotensive effects of amifostine may be strengthened by blood pressure reducing medications. Treatment: Stop taking blood pressure medications at least 24 hours before taking amifostine. If taking blood pressure medicine cannot be stopped, amifostine should be avoided.
Antifungal Agents (Azole Derivatives, Systemic) Itraconazole may make calcium channel blockers more toxic or harmful. Particularly itraconazole has the potential to worsen the inotropic side effects of verapamil and diltiazem. Calcium channel blocker metabolism can be decreased by antifungal agents (azole derivatives systemic). Fluconazole and isavuconazonium probably have less powerful effects than other azoles. In different monographs, these are covered. Management: Concurrent use of itraconazole and felodipine is not permitted under any circumstances. Any medicine combination involving these ones should undergo routine monitoring. Reduced dosages of calcium channel blockers might also be required. Fluconazole and isavuconazonium sulphate are exceptions.
Antihepaciviral Combination Products Amlodipine serum levels might rise. When using an antihepaciviral combination treatment, reduce the dosage of amlodipine by at least half and keep an eye out for any heightened amlodipine side effects (such as hypotension).
CarBAMazepine Dihydropyridine, a calcium channel blocker, may speed up metabolism. Treatment: Patients taking calcium channel blockers concurrently with carbamazepine should think about adjusting their doses (CCB). The Canadian labelling for nimodipine expressly forbids taking it alongside carbamazepine.
Strong CYP3A4 Inducers May speed up CYP3A4 substrate metabolism (High Risk with Inducers). Management: You might think about switching out one of the interfering medications with another medication. Contraindications may apply to specific combinations. the relevant manufacturer's label.
Dabrafenib High chance that inducers will lower serum CYP3A4 substrate levels. Management: If at all possible, look for CYP3A4 substrate substitutes. It is best to avoid concurrent therapy wherever possible. Keep a close eye on the substrate's clinical effects (especially therapeutic effects).
Enzalutamide High chance that inducers will lower serum levels of CYP3A4 substrates. Management: Steer clear of using enzalutamide and CYP3A4 substrates simultaneously. When utilising enzalutamide or any other CYP3A4 sub-substance, you should use caution.
Fosphenytoin Fosphenytoin serum levels can rise in response to calcium channel blockers. Management: After stopping the use of a calcium channel blocker (CCB), monitor for a decrease in the effects of phenytoin. Keep an eye out for diminished CCB therapeutic effects. The Canadian labelling for nimodipine specifically forbids the use of phenytoin.
Lomitapide CYP3A4 inhibitors may result in a rise in lomitapide (Weak). Treatment: Patients who are currently taking lomitapide 5 mg/day can keep doing so. Patients must cut their lomitapide dosage in half if they are taking 10 mg or more per day. then you can change the dosage of lomitapide.
Lorlatinib High chance that inducers will lower serum levels of CYP3A4 substrates. Management: Avoid taking lorlatinib at the same time as any CYP3A4 substrates. A therapeutic failure or negative clinical outcomes could result from even a modest drop in serum concentrations.
Antibiotics with Macrolide The metabolic activity of calcium channel blockers may be reduced. Use a non-interacting macrolide for management. The Canadian labelling for felodipine expressly advises against using it in conjunction with clarithromycin. Fidaxomicin, Roxithromycin, and Spiramycin are exceptions to the rule; azithromycin (systemic).
MiFEPRIStone High chance that inhibitors will raise serum levels of CYP3A4 substrates. Management: During and two weeks after mifepristone treatment, reduce doses of CYP3A4 substrates and keep an eye out for elevated amounts or toxicity. Avoid ergotamine and dihydroergotamine.
Mitotane High chance that inducers will lower serum levels of CYP3A4 substrates. Treatment: Patients on mitotane may need to significantly change their CYP3A4 Substrates dosage.
Obinutuzumab The effects of blood pressure lowering medications may become more hypotensive as a result. Treatment: Starting 12 hours before the obinutuzumab injection and continuing for 1 hour after the infusion, you may temporarily stop taking blood pressure-lowering medications.
Phenytoin The serum level of phenytoin can rise after taking calcium channel blockers. Phenytoin may reduce the levels of calcium channel blockers in the serum. Management: Nimodipine and nifedipine shouldn't be used with phenytoin. With any concurrent use, it's crucial to monitor for phenytoin toxicities and/or diminished calcium channel blocking effects.
Pitolisant High chance that inducers will lower serum levels of CYP3A4 substrates Avoid combining a CYP3A4 substrate with a low therapeutic index with pitolisant. Pitolisant and other CYP3A4 sub-substances shouldn't be mixed.
Rifamycin Derivatives A reduction in serum calcium channel blockers may result from this. The main culprit here is an oral calcium channel blocker. Management: Using rifampin with certain calcium channel blockers is not advised according to the labelling in the US and Canada. Look up the relevant labelling.
Simvastatin AmLODIPine may increase the effects of simvastatin. Amlodipine and simvastatin shouldn't be taken concurrently. Adults should not take more than 20 mg of simvastatin daily in combination.
Sincalide Sincalide may be less effective if drugs that affect gallbladder function are taken. Management: Before Sincalide is used to stimulate the gallbladder, discontinue any drugs that affect gallbladder motility.
St John's Wort High chance that inducers will lower serum CYP3A4 substrate levels. Management: You might think about switching out one of the interfering medications with another medication. Contraindications may apply to specific combinations. the relevant manufacturer's label.
Stiripentol High chance that inhibitors will raise serum levels of CYP3A4 substrates. Treatment: Steer clear of using stiripentol with CYP3A4 substrates that have a limited therapeutic index. This is done to prevent negative consequences and toxicity. Any CYP3A4 substrate that is administered in conjunction with stiripentol should be strictly monitored.

Risk Factor X (Avoid Combination)

 
Bromperidol The hypotensive effects of bromperidol may be strengthened by blood pressure-lowering medications. The hypotensive effects of blood pressure-lowering medications may be lessened by bromperidol.
Conivaptan High risk of Inhibitors causing an increase in serum CYP3A4 Substrates concentrations
Fusidic Acid (Systemic). High risk of Inhibitors causing an increase in serum CYP3A4 Substrates concentrations
Idelalisib High risk of Inhibitors causing an increase in serum CYP3A4 Substrates concentrations
Pimozide Pimozide may be increased by CYP3A4 inhibitors (Weak).

Monitoring prameters:

  • As you titrate the dose upward until the goal blood pressure is reached or the maximum dose is reached, keep an eye on your heart rate and blood pressure.

How to Administer Amlodipine?

  • Amlodipine may be taken without regards to meals.

Mechanism of action of Amlodipine:

  • Amlodipine blocks calcium ions from entering the vascular smooth muscle's "slow channel" during depolarization.
    As a result, the coronary smooth muscle relaxes (and coronary blood flow).
  • Patients with vasospastic gina will experience an increase in oxygen delivery to their myocardium.
  • Additionally, it causes peripheral arterial vasodilation, which lowers peripheral resistance and blood pressure, by acting directly on the smooth muscle of the vascular artery.

The onset of action is about 24 to 48 hours.

The duration of action varies from 24 to 72 hours. It is well absorbed and is 93% protein bound.

Metabolism is mainly via the liver and the bioavailability varies from 64 to 90%.

Half-life elimination varies from 30 to 50 hours and is prolonged in patients with hepatic impairment.

The time to peak plasma concentration is around 6 to 12 hours

Excretion is mainly via Urine.   

International brands of Amlodipine:

  • A-B Vask
  • Actapin
  • Adipin
  • Aforbes
  • Agen
  • Aladin
  • Alopine
  • Alozur
  • Amaday
  • Ambesyl
  • Amcal
  • Amcard
  • Amdepin
  • Amdhapine
  • Amdipin
  • Amdixal
  • Amedin
  • Amilo
  • Amlate
  • Amlibon
  • Amlibon BES
  • Amlo-H10
  • Amlo-H5
  • Amlo-M
  • Amlober
  • Amloc
  • Amlocar
  • Amlocard
  • Amlocor
  • Amlodac
  • Amlodar
  • Amlode
  • Amlodigamma
  • Amlodin
  • Amlodine
  • Amlodno
  • Amloget
  • Amlogrix
  • Amlong
  • Amlopine
  • Amlopres
  • Amlopress
  • Amlor
  • Amlorine
  • Amlostar
  • Amlosyn
  • Amlotan
  • Amlotens
  • Amlotrene
  • Amlovasc
  • Amlovasc 5
  • Amlow
  • Amlozen
  • Amodin
  • Amodipin
  • Amopress
  • Ampliron
  • Amtas
  • Amvasc
  • Amze
  • An Nei
  • Zhen
  • Anoldin
  • Anydipine
  • Ao Wan Lu
  • Arainno
  • Asomex-5.0
  • Astudal
  • Avevasc
  • Avistar
  • Awar
  • Bezam
  • Cab
  • Calbloc
  • Calchek
  • Calvase
  • Cardilopin
  • Cardol
  • Cobisk
  • Cordarene
  • Covasc
  • CP-Lovac
  • Cydipin
  • DAILYvasc
  • Deten
  • Dipsope
  • Du.Q
  • Duactin 5
  • Ertensi
  • Evasc
  • Fulopin
  • Gensia
  • Gravask
  • Hovasc
  • Istin
  • Istolde
  • Konipid
  • Lama
  • Licodipin
  • Lodibes
  • Lodip
  • Lodipam
  • Lofral
  • Lomanor
  • Lotense
  • Lowdipine
  • Lowrac
  • Lowvasc
  • Lupin
  • Narvin
  • Nexus
  • Noloten
  • Nopidin
  • Nor-Lodipina
  • Nordip
  • Normodipine
  • Norvapine
  • Norvas
  • Norvasc
  • Norvasc ODT
  • Norvask
  • Novaspin
  • Odasyl
  • Opivask
  • Prelod
  • Presilam
  • Provasc
  • Remedopin S
  • Sinnorvapin
  • Sinop
  • Sistopress
  • Stadovas
  • Stamlo
  • Stamlo-10
  • Tenox
  • Tensiblat
  • Terloc
  • Varodipine
  • Vascodipine
  • Vascor
  • Vasocal
  • Vasotop
  • Vasten
  • Zynor
  • ACCEL-Amlodipine
  • ACT Amlodipine
  • AG-Amlodipine
  • APO-Amlodipine
  • Auro-Amlodipine
  • BIO-Amlodipine
  • DOM-Amlodipine
  • GD-Amlodipine
  • JAMP-Amlodipine
  • M-Amlodipine
  • Mar-Amlodipine
  • MINT-Amlodipine
  • MYLAN-Amlodipine
  • Norvasc
  • NRA-Amlodipine
  • PHARMA-Amlodipine
  • PHL-Amlodipine
  • PMS-Amlodipine
  • Priva-Amlodipine
  • Q-Amlodipine
  • RAN-Amlodipine
  • SANDOZ Amlodipine
  • Septa-Amlodipine
  • TEVA-Amlodipine
  • VAN-Amlodipine

Amlodipine Brands in Pakistan:

Amlodipine (Besylate) [Tabs 5 mg]

ADOPTIN FYNK PHARMACEUTICALS
ADOPTINE TREAD PHARMACEUTICALS PVT LTD
AMDIPINE NABIQASIM INDUSTRIES (PVT) LTD.
AMDIPINE NABIQASIM INDUSTRIES (PVT) LTD.
AMDOCAL BEX PHARMA (PVT) LTD.
AML BATALA PHARMACEUTICALS.
AMLOBEST PEARL PHARMACEUTICALS
AMLOCARD PHARMATEC PAKISTAN (PVT) LTD.
AMLOD ATCO LABORATORIES LIMITED
AMLODIP SEARLE PAKISTAN (PVT.) LTD.
AMLOFINE MEDLINE HEALTH CARE
AMLOMAK MAKSON PHARMACEUTICALS
AMLOMED MEDIFINE LABORATORIES
AMLOPAL ALSON PHARMACEUTICALS
AMLOPIN Shaigan Pharmaceuticals (PVT) LTD
AMLOPRO WNS FIELD PHARMACEUTICALS
AMLOSAF SAAAF PHARMACEUTICALS
AMLOTAC HYGEIA PHARMACEUTICALS
AMLOWAN NAWAN LABORATORIES (PVT) LTD.
AMODIP MASS PHARMA (PRIVATE) LIMITED
AMOLIN F.M. PHARMACEUTICALS INTERNATIONAL
AMOTEL IDEAL PHARMACEUTICAL INDUSTRIES
AMPRESS BARRETT HODGSON PAKISTAN (PVT) LTD.
AMRX SIZA INTERNATIONAL (PVT) LTD.
AMVASC ARIES PHARMACEUTICALS (PVT) LTD
AMVAZAM CIRIN PHARMACEUTICALS (PVT) LTD.
ANAM TAGMA PHARMA (PVT) LTD.
ANGIPIN STANDPHARM PAKISTAN (PVT) LTD.
ARDEPIN ARDIN PHARMACEUTICALS
AVIANT GRAY`S PHARMACEUTICALS
BESCARD FLOW PHARMACEUTICALS (PVT) LTD.
BESIPINE CSH PHARMACEUTICALS-NORTH (PVT) LTD
CA-B SAYDON PHARMACEUTICAL INDUSTRIES (PVT) LTD.
CABOK PLATINUM PHARMACEUTICALS (PVT.) LTD.
CALOC BOSCH PHARMACEUTICALS (PVT) LTD.
CANTA SHAHEEN PHARMACEUTICALS
CARDIOCARE JAWA PHARMACEUTICALS(PVT) LTD.
CARDIOSIL HIMONT PHARMACEUTICALS (PVT) LTD.
CARDIOVASC WERRICK PHARMACEUTICALS
CO-CARDIOVASC WERRICK PHARMACEUTICALS
CORAM BROOKES PHARMACEUTICAL LABORATORIES (PAK.) LTD.
CORCONT SWISS PHARMACEUTICALS (PVT) LTD.
CORDFED FEDRO PHARMACEUTICAL
CORDIUM PHARMIX LABORATORIES (PRIVATE) LIMITED.
CORINOR P.D.H. PHARMACEUTICALS (PVT) LTD.
DIPIVAS FASSGEN PHARMACEUTICALS
ENALATAC HYGEIA PHARMACEUTICALS
ENDIP ENGLISH PHARMACEUTICALS INDUSTRIES
ENVAS LOWITT PHARMACEUTICALS (PVT) LTD
FARLOD UN PHARMA INTERNATIONAL
G-SAC GLOBAL PHARMACEUTICALS
HARTVASC-PLUS SCOTMANN PHARMACEUTICALS
HIBIOHIT UNIPHARMA (PVT) LTD.
HIBLOHIT UNIPHARMA (PVT) LTD.
HODIP HEAL PHARMACEUTICALS PVT LTD
HYPERCOR NOVINS INTERNATIONAL
HYPOTIN DON VALLEY PHARMACEUTICALS (PVT) LTD.
HYPRES DON VALLEY PHARMACEUTICALS (PVT) LTD.
LEAF SCOTMANN PHARMACEUTICALS
LIPINOX FRIENDS PHARMA (PVT) LTD
LODIPIN SCHAZOO ZAKA
LODIVASC DOSACO LABORATORIES
LODOPIN MERCK PRIVATE LTD.
LOPIN AMBROSIA PHARMACEUTICALS
MEGADIP MEGA PHARMACEUTICALS (PVT) LTD
MEVODIP ALLIANCE PHARMACEUTICALS (PVT) LTD.
MIDOPINE WELMARK PHARMACEUTICALS
MIOSIL EUROPAK PHARMA (PVT) LTD
MLOW SCILIFE PHARMA (PRIVATE) LTD
MODOPINE ASKARI PHARMACEUTICALS.
NENCURE NENZA PHARMACEUTICALS (PVT) LIMITED
NEOPRES BIOGENICS PAKISTAN (PVT) LTD.
NORVASC PFIZER LABORATORIES LTD.
NORVASC PFIZER LABORATORIES LTD.
ONATO SAMI PHARMACEUTICALS (PVT) LTD.
ORELOP FLOW PHARMACEUTICALS (PVT) LTD.
QUVASC NOVARTIS PHARMA (PAK) LTD
RASDIPIN RASCO PHARMA
RAVAPINE RAKAPOSHI PHARMACEUTICAL (PVT) LTD.
RAVAPINE RAKAPOSHI PHARMACEUTICAL (PVT) LTD.
RYDEM WERRICK PHARMACEUTICALS
S-DIP SHROOQ PHARMACEUTICALS
SALOME LAHORE CHEMICAL & PHARMACEUTICAL WORKS (PVT) LTD
SICKNOR EVEREST PHARMACEUTICALS
SOFVASC WILSONS PHARMACEUTICALS
SOFVASC WILSONS PHARMACEUTICALS
SOFVASC PLUS WILSONS PHARMACEUTICALS
SWINT LIBRA PHARMACEUTICALS (PVT) LTD
TAROVASC EVEREST PHARMACEUTICALS
VASIC MIRACLE PHARMACEUTICALS(PVT) LTD
VASODIL PHARMEDIC (PVT) LTD.
VASODIPINE ALFALAH PHARMA (PVT) LTD.
VESPIN AMSON VACCINES & PHARMA (PVT) LTD.
WINCORAM POLYFINE CHEMPHARMA (PVT) LTD.
ZAMLO ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.
ZODIP ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.

 

Amlodipine (Besylate) [Tabs 10 mg]

AMDIPINE Nabiqasim Industries (PVT) LTD.
AMDIPINE Nabiqasim Industries (PVT) LTD.
AMLOBEST Pearl Pharmaceuticals
AMLOCARD PHARMATEC PAKISTAN (PVT) LTD.
AMLODIP SEARLE PAKISTAN (PVT.) LTD.
AMLOFINE MEDLINE HEALTH CARE
AMLOMAK MAKSON Pharmaceuticals
AMLOMED MEDIFINE LABORATORIES
AMLOPAL ALSON Pharmaceuticals
AMLOPRO WNS FIELD Pharmaceuticals
AMLOSAF SAAAF Pharmaceuticals
AMLOSYL LEXICON Pharmaceuticals(PVT) LTD.
AMLOTAC HYGEIA Pharmaceuticals
AMODIP MASS Pharmaceuticals(PRIVATE) LIMITED
AMOTEL IDEAL Pharmaceuticals INDUSTRIES
AMPRESS BARRETT HODGSON PAKISTAN (PVT) LTD.
AMRX SIZA INTERNATIONAL (PVT) LTD.
AMVASC ARIES PHARMACEUTICALS (PVT) LTD
ANAM TAGMA PHARMA (PVT) LTD.
ANGIPIN STANDPHARM PAKISTAN (PVT) LTD.
ARDEPIN ARDIN Pharmaceuticals
AVIANT GRAY`S Pharmaceuticals
BESCARD FLOW Pharmaceuticals(PVT) LTD.
CA-B SAYDON Pharmaceuticals INDUSTRIES (PVT) LTD.
CABOK PLATINUM Pharmaceuticals(PVT.) LTD.
CALOC BOSCH Pharmaceuticals(PVT) LTD.
CANTA SHAHEEN Pharmaceuticals
CARDIOCARE JAWA Pharmaceuticals (PVT) LTD.
CARDIOSIL HIMONT Pharmaceuticals(PVT) LTD.
CARDIOVASC WERRICK Pharmaceuticals
CORAM BROOKES Pharmaceuticals LABORATORIES (PAK.) LTD.
CORCONT SWISS Pharmaceuticals (PVT) LTD.
CORINOR P.D.H. Pharmaceuticals(PVT) LTD.
DIPCARE SILVER OAK CORPORATION.
DIPIVAS FASSGEN PHARMACEUTICALS
ENALATAC HYGEIA PHARMACEUTICALS
ENDIP ENGLISH PHARMACEUTICALS INDUSTRIES
ENVAS LOWITT PHARMACEUTICALS (PVT) LTD
FARLOD UN PHARMA INTERNATIONAL
HARTVASC-PLUS SCOTMANN Pharmaceuticals
HODIP HEAL PharmaceuticalsPVT LTD
HYPERCOR NOVINS INTERNATIONAL
HYPOCARD CAYLEX Pharmaceuticals (PVT) LTD.
HYPOTIN DON VALLEY Pharmaceuticals(PVT) LTD.
HYPRES DON VALLEY Pharmaceuticals(PVT) LTD.
LODIPIN SCHAZOO ZAKA
LODOPIN MERCK PRIVATE LTD.
LOPIN AMBROSIA Pharmaceuticals
MEGADIP MEGA Pharmaceuticals(PVT) LTD
MIDOPINE WELMARK Pharmaceuticals
MIOSIL EUROPAK PHARMA (PVT) LTD
MLOW SCILIFE PHARMA (PRIVATE) LTD
MODOPINE ASKARI PHARMACEUTICALS.
NENCURE NENZA PHARMACEUTICALS (PVT) LIMITED
NEOPRES BIOGENICS PAKISTAN (PVT) LTD.
NORVASC PFIZER LABORATORIES LTD.
NORVASC PFIZER LABORATORIES LTD.
ONATO SAMI Pharmaceuticals (PVT) LTD.
ORELOP FLOW Pharmaceuticals(PVT) LTD.
PROVASC GENOME Pharmaceuticals (PVT) LTD
QUVASC NOVARTIS PHARMA (PAK) LTD
RAVAPINE RAKAPOSHI Pharmaceuticals(PVT) LTD.
RAVAPINE RAKAPOSHI Pharmaceuticals(PVT) LTD.
RYDEM WERRICK Pharmaceuticals
S-DIP SHROOQ Pharmaceuticals
SICKNOR EVEREST Pharmaceuticals
SOFVASC WILSONS Pharmaceuticals
SWINT LIBRA Pharmaceuticals(PVT) LTD
TAROVASC EVEREST Pharmaceuticals
VASIC MIRACLE Pharmaceuticals (PVT) LTD
VATLO ALKEMY Pharmaceuticals LABORATORIES (PRIVATE) LTD.
WINCORAM POLYFINE CHEMPHARMA (PVT) LTD.

 

Amlodipine (Besylate) [Tabs 2.5 mg]

AMLOCARD PHARMATEC PAKISTAN (PVT) LTD.
AMODIP MASS PHARMA (PRIVATE) LIMITED
CARDIOVASC WERRICK Pharmaceuticals
HARTVASC-PLUS SCOTMANN Pharmaceuticals
LODOPIN MERCK PRIVATE LTD.
QUVASC NOVARTIS PHARMA (PAK) LTD
RYDEM WERRICK Pharmaceuticals
SOFVASC WILSONS Pharmaceuticals